Keywords: Takeda, AMAG Pharma, Feraheme, Anemia, Galantamine, Alzheimer's, Johnson & Johnson
Takeda buys rights to AMAG Pharma’s Feraheme in select ex-US territories, including Europe, for up to $280 million; and R113675 in Japan from J&J
Article | 06 April 2010
Japan’s largest drugmaker Takeda Pharmaceutical has reached agreement with USA-based AMAG Pharmaceuticals (which specializes in the development of compounds ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
